Zai Lab Company Insiders
ZLAB Stock | USD 36.40 0.91 2.56% |
Zai Lab employs about 1.9 K people. The company is managed by 18 executives with a total tenure of roughly 4361 years, averaging almost 242.0 years of service per executive, having 103.83 employees per reported executive. Analysis of Zai Lab's management performance can provide insight into the company performance.
Zai Lab Management Team Effectiveness
The company has return on total asset (ROA) of (0.155) % which means that it has lost $0.155 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.3205) %, meaning that it created substantial loss on money invested by shareholders. Zai Lab's management efficiency ratios could be used to measure how well Zai Lab manages its routine affairs as well as how well it operates its assets and liabilities.Zai Lab Workforce Comparison
Zai Lab is rated first in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 143,813. Zai Lab claims roughly 1,869 in number of employees contributing just under 2% to equities under Health Care industry.
The company has Profit Margin (PM) of (0.6) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.53) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.53. Zai Lab Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Zai Lab insiders, such as employees or executives, is commonly permitted as long as it does not rely on Zai Lab's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Zai Lab insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Yajing Chen over a week ago Disposition of 2675 shares by Yajing Chen of Zai Lab at 36.132 subject to Rule 16b-3 | ||
Yajing Chen over a week ago Disposition of 6250 shares by Yajing Chen of Zai Lab subject to Rule 16b-3 | ||
Leung Nisa over two weeks ago Acquisition by Leung Nisa of 10831 shares of Zai Lab subject to Rule 16b-3 | ||
Joshua Smiley over a month ago Disposition of 32062 shares by Joshua Smiley of Zai Lab subject to Rule 16b-3 | ||
Ying Du over a month ago Disposition of 46389 shares by Ying Du of Zai Lab at 0.6 subject to Rule 16b-3 | ||
Ying Du over a month ago Disposition of 50000 shares by Ying Du of Zai Lab at 0.6 subject to Rule 16b-3 | ||
Joshua Smiley over two months ago Disposition of 4352 shares by Joshua Smiley of Zai Lab at 16.673 subject to Rule 16b-3 | ||
Edmondson Frazor Titus Iii over three months ago Disposition of 2671 shares by Edmondson Frazor Titus Iii of Zai Lab subject to Rule 16b-3 |
Zai Lab Notable Stakeholders
A Zai Lab stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Zai Lab often face trade-offs trying to please all of them. Zai Lab's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Zai Lab's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Rafael MD | President Development | Profile | |
Peter Huang | Chief Officer | Profile | |
Dr MBA | Chief Officer | Profile | |
Joshua Smiley | Chief Officer | Profile | |
Frazor III | Chief Sec | Profile | |
Christine Chiou | Senior Relations | Profile | |
Harald MD | Autoimmune Neuroscience | Profile | |
Robert MD | Chief Oncology | Profile | |
Ann JD | Chief Officer | Profile | |
Ning MD | Executive Operations | Profile | |
DABT MD | Chief RD | Profile | |
Yajing Chen | Chief Officer | Profile | |
Alan MD | Pres Oncology | Profile | |
JD III | Chief Secretary | Profile | |
Ki Cho | Chief Officer | Profile | |
MBA MBA | Chief Officer | Profile | |
Ying Du | Chairperson Founder | Profile | |
Tong Zhu | Chief China | Profile |
About Zai Lab Management Performance
The success or failure of an entity such as Zai Lab often depends on how effective the management is. Zai Lab management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Zai management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Zai management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. Zai Lab Limited was incorporated in 2013 and is headquartered in Shanghai, China. Zai Lab operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 1951 people.
Please note, the presentation of Zai Lab's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Zai Lab's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Zai Lab's management manipulating its earnings.
Zai Lab Workforce Analysis
Traditionally, organizations such as Zai Lab use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Zai Lab within its industry.Zai Lab Manpower Efficiency
Return on Zai Lab Manpower
Revenue Per Employee | 213.5K | |
Revenue Per Executive | 22.2M | |
Net Loss Per Employee | 137.6K | |
Net Loss Per Executive | 14.3M | |
Working Capital Per Employee | 401.9K | |
Working Capital Per Executive | 41.7M |
Complementary Tools for Zai Stock analysis
When running Zai Lab's price analysis, check to measure Zai Lab's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Zai Lab is operating at the current time. Most of Zai Lab's value examination focuses on studying past and present price action to predict the probability of Zai Lab's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Zai Lab's price. Additionally, you may evaluate how the addition of Zai Lab to your portfolios can decrease your overall portfolio volatility.
CEOs Directory Screen CEOs from public companies around the world | |
Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments |